This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this article, Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026.
I started my journey in chemistry – first as an undergraduate and then in my PhD programme at the University of Houston, where I focused on organicchemistry and nucleic acids chemistry. Can you tell us about your journey in the field of STEM and the challenges you encountered along the way?
A graduate of the Hebrew University of Jerusalem, he earned a Bachelor of Science in chemistry and physics and a Master of Science in physical organicchemistry before completing a Doctor of Philosophy in 1971. Elmaleh has contributed to more than 130 book chapters, scientific papers, and professional journal articles.
He continued his education at Indiana University, where he completed a Master of Arts in botany in 1964, and a Doctor of Philosophy in organicchemistry in 1965. He attributes his success to good fortune and hard work, and hopes to see some of his patented compounds gain approval and reach market readiness in the coming years.
This article will discuss various molecular design strategies for reducing BBB efflux and increasing passive permeability. Dennis obtained his PhD in OrganicChemistry from the University of Göttingen in 2013 specializing in carbohydrate chemistry and transition-metal catalysis.
Dr Lopa Bakrania brings over 18 years of experience in pharmaceutical process chemistry and CMC regulatory affairs. As Executive Director of CMC Regulatory Affairs at Biohaven , she leads efforts to develop innovative therapies from the clinic to market approval. When I joined, I was one of only five women on a team of 150 men.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content